On Tuesday, Dyax Corp., a biotherapeutic drug firm, announced that it has managed to bag an approval by the US Food and Drug Administration to market Kalbitor, the company's drug manufactured especially for the treatment of Angioedema, a hereditary genetic disorder, in patients of age group 16 and above.
Characterized by undue accumulation of fluids outside blood vessels in the body, the disease causes extreme swelling in the intestinal tract or airway. As per the company, the medicine is the first injectable treatment for the disorder approved in the US.
As a part of the approval, the firm has decided to set up a program which will aim at informing users about the risks associated with anaphylatic shock, and the importance of determining and knowing the difference between hypersensitivity to the drug and a hereditary angioedema attack, so that users are better aware.
Currently, Kalbitor is also being tested as a possible medicine to prevent blood loss during a particular type of heart surgery.
Post the announcement of approval, Dyax shared hiked by 38%, or $1.33 in after-hours trading.
Good News USA
- Vodafone NZ’s new ‘Red Home’ packages will offer UFB and 150 TV channels
- Vodafone NZ’s full-year profit plunged by more than two-thirds to $56 million
- Vodafone adding 34 European countries to ‘AU$5 per day’ international roaming option
- Telstra launches its new ‘Every Day Connect Data Share Packages’
- Voyager signs “multimillion-dollar deal” with submarine cable group Hawaiki